UK antitrust watchdog clears Roche/Spark deal — but what is the FTC thinking?
Roche has gained the blessing from the UK antitrust watchdog to proceed with its $4.3 billion acquisition of Spark, just in time for the latest deadline the pharma giant has set for Spark’s investors to tender their shares following 10 delays.
The Competition and Markets Authority confirmed speculation and rumors — pretty much assumed true at this point — that they had been looking into the competitive landscape for hemophilia A treatments. After concluding that there will still be an adequate choice of alternatives even after the makers of Hemlibra and a potential gene therapy are blended into one, regulators gave the deal an unconditional clearance.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.